Total trials
547
Active
82
Phase 3
29
Total enrollment
99,901
Pipeline matrix
Showing 35 of 35 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Vancomycin 1000 MG | — | — | — | — | — | 1 | |
| KleanLyte | — | — | — | — | — | 1 | |
| Bi-PegLyte | — | — | — | — | — | 1 | |
| Heparin | — | — | — | — | — | 2 | |
| Methoxyflurane - Penthrox | — | — | — | — | — | 1 | |
| Percocet Pill | — | — | — | — | — | 1 | |
| Lorazepam | — | — | — | — | — | 1 | |
| Lemborexant | — | — | — | — | — | 1 | |
| Beta-3 agonists | — | — | — | — | — | 1 | |
| MPL-001 | — | — | — | — | — | 2 | |
| Standard dressing | — | — | — | — | — | 2 | |
| PluroGel | — | — | — | — | — | 2 | |
| Levofloxacin | — | — | — | — | 3 | ||
| Tranexamic acid | — | — | — | — | 2 | ||
| MPL-005 | — | — | — | — | — | 1 | |
| MPL-009 | — | — | — | — | — | 1 | |
| CBD Isolate | — | — | — | — | — | 1 | |
| CBD CHE | — | — | — | — | — | 1 | |
| Phenylephrine | — | — | — | — | — | 1 | |
| Adjuvant Immunoradiotherapy | — | — | — | — | — | 1 | |
| Adjuvant chemoradiotherapy | — | — | — | — | — | 1 | |
| Nitrous Oxide Inhalant Product | — | — | — | — | — | 1 | |
| Fluconazole 150 mg | — | — | — | — | — | 1 | |
| Boric Acid Supp,Vag | — | — | — | — | — | 1 | |
| Morphine | — | — | — | — | — | 2 | |
| Azithromycin | — | — | — | — | — | 1 | |
| curcumin, omega-3, and vitamin D | — | — | — | — | — | 1 | |
| Medical Cannabis | — | — | — | — | — | 1 | |
| Behavioral and drugs already approved and available for diabetes management | — | — | — | — | — | 1 | |
| Buspirone 10 Mg Oral | — | — | — | — | — | 1 | |
| Triazolam 0.25 MG Oral | — | — | — | — | — | 1 | |
| Bupivacaine 0.75% in Dextrose Inj 8.25% | — | — | — | — | — | 1 | |
| Bupivacaine 0.25% Preservative-Free Injectable Solution | — | — | — | — | — | 1 | |
| Bupicavaine 0.125% epidural solution | — | — | — | — | — | 1 | |
| Hydromorphone 10 mcg/mL epidural solution | — | — | — | — | — | 1 |
Next readouts
- 2025-06-20
- 2025-12
- 2025-12
- 2025-12
- 2025-12-31
- 2026-04-18
- 2026-07
- 2026-10-01
- 2026-10-30
- 2026-12
Top conditions
- Obesity16
- Anxiety11
- Healthy11
- Depression10
- Type 2 Diabetes10
- Hypercholesterolemia8
- Cardiovascular Diseases7
- Diabetes Prevention7
Frequently asked questions about University of Manitoba
- How many clinical trials does University of Manitoba have on ClinicalTrials.gov?
- University of Manitoba is listed as the lead sponsor on 547 clinical trials in ClinicalTrials.gov, 82 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Manitoba's trials are in Phase 3?
- 29 of University of Manitoba's trials are in Phase 3, spread across 35 active drug programs.
- What therapeutic areas does University of Manitoba focus on?
- University of Manitoba's most-studied conditions on ClinicalTrials.gov are Obesity, Anxiety, Healthy, Depression, Type 2 Diabetes.
- When are University of Manitoba's next clinical trial readouts?
- University of Manitoba has 10 upcoming primary-completion readouts tracked here; the soonest is “Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer”, expected around 2025-06-20.